EP.11.03 First Line Chemo-Immunotherapy Prognostic Factors Predicting Non Small Cell Lung Cancer Overall Survival
Riccardo Ronga(Ospedale Antonio Cardarelli), Ferdinando Riccardi(Ospedale Antonio Cardarelli), P. Maione(Azienda Ospedaliera S.Giuseppe Moscati), G. Viscardi(Ospedale Monaldi), Francesco Jacopo Romano(Federico II University Hospital), Cesare Gridelli(Azienda Ospedaliera S.Giuseppe Moscati), Severo Campione(Federico II University Hospital), Berta Miranda(Universitat Autònoma de Barcelona), Fabiana Vitiello(Ospedale Monaldi), Angelo Vaia(Ospedale San Carlo), G. Guggino(Ospedale Antonio Cardarelli), Francesca Ambrosio(Azienda Ospedaliero-Universitaria Careggi), A. Farinaro(Federico II University Hospital)
Cited by 0
Related Papers
Non-small-cell lung cancer
|Nature Reviews Disease Primers|2015|1.1k
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
|The Lancet Oncology|2012|550
First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial
|Journal of Clinical Oncology|2012|234
Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial
|Journal of Clinical Oncology|2017|186
Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective Study
|The Journal of Clinical Endocrinology & Metabolism|2019|180